Contraceptives, Oral
Mayne Pharma Faces FDA Action Over ‘Misleading’ Drug Safety Claims Ahead of $430M Buyout
Mayne Pharma; FDA; misleading claims; Nextstellis; birth control pill; drug safety; buyout; Cosette Pharmaceuticals
FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill
United States Food and Drug Administration, Califf, Unspecified Abortion, Contraceptives, Oral, Accelerated, Artificial Intelligence, RIFs, Infrequent, Agencies
Trump pledges his support for a change to the IRA long sought by drugmakers
IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare
Pliant and Acelyrin Adopt Poison Pill Defenses Against Potential Concentra Buyout
Poison pill, Concentra Biosciences, Tang Capital Partners, Acelyrin, Pliant Therapeutics, hostile takeover defense
Roche’s Obesity Pill Candidate Faces Safety Concerns Amid Promising Efficacy Results
Roche, Obesity Pill, Safety Concerns, Efficacy Data, CT-996, Side Effects, Nausea, Vomiting, Gastrointestinal Issues